Meiji (2269) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
6 Aug, 2025Executive summary
Net sales for Q1 were JPY 273.5–273.6 billion, down 1.8% year-over-year, with operating profit at JPY 17.7 billion, down 13.4%. Profit attributable to owners fell 27.6% to JPY 10.0–10.1 billion.
Operating profit and EPS declined due to cost inflation and higher tax expenses.
The operating environment improved in hiring and wages, but consumer thrift increased due to higher living costs and global uncertainties.
The company is advancing its Medium-Term Business Plan, focusing on value-added products, B2B expansion, and overseas profitability.
Financial highlights
Gross profit for Q1 was JPY 80.0 billion, down 2.4% year-over-year; SG&A expenses rose 1.2%.
EPS for Q1 was JPY 37.27, down from JPY 50.23; operating profit margin declined to 6.5% from 7.4%.
Comprehensive income dropped 61.9% year-over-year to JPY 7.95 billion.
Free cash flow was negative at JPY 19.5 billion, a further decline from negative JPY 9.6 billion a year earlier.
Profit attributable to owners of parent fell 27.6% to JPY 10.0–10.1 billion; EPS decreased to JPY 37.27.
Outlook and guidance
Full-year net sales forecast at JPY 1,195.0 billion (+3.5% YoY); operating profit projected at JPY 91.0 billion (+7.4% YoY); profit attributable to owners at JPY 54.0 billion (+6.3%).
EPS for the year expected at JPY 197.80; dividend per share planned at JPY 105.00.
No revisions to H1 or full-year guidance.
Latest events from Meiji
- Impairment in China drives restructuring, with renewed focus on growth, ROE, and innovation.2269
Investor presentation25 Mar 2026 - Operating profit rose on Food segment strength, but net profit fell on higher costs and impairment.2269
Q3 202612 Feb 2026 - Pharmaceuticals drove profit growth as food margins fell; full-year outlook and share cancellation steady.2269
Q2 202515 Jan 2026 - Operating profit beat plan, but sales forecast lowered amid cost pressures and ongoing reforms.2269
Q2 202617 Nov 2025 - Sales and profit rose, led by pharmaceuticals, despite food margin pressures.2269
Q1 202513 Jun 2025 - Sales and profit growth continue, with higher dividends and strategic investments ahead.2269
Q4 20256 Jun 2025 - Sales growth offset by pharma and vaccine losses; outlook remains cautious.2269
Q3 20256 Jun 2025